# Autonomous Session — 2026-06-08 (12:06Z → 14:06Z)

Goal: get the pipeline to "best brief in the world" confidence by implementing the validated
fix list from four independent QM/audit agents, THEN run a test on 5 likely-UNDERVALUED stocks
(to settle whether the prior all-below-market results were selection or a method bias).

## Status report #1 — 12:19Z

### Fixes implemented & pushed (the validated defect list → confidence)
The four agents (3 expert auditors + CIO + general-investment-QM + biotech-science-QM +
functional-code-QM) converged on a clear defect set. All now fixed (commits d2b8980 → 35cf9b5):

1. **Price-blinding made architectural** (the #1 systemic issue, 4 agents):
   - get_peers: stripped raw market_cap/price (kept comparison multiples).
   - get_insider_activity: dropped the Form-4 transaction price (≈ market quote).
   - research subagent + get_news: price-blind instruction + conservative regex backstop
     (redacts price-target/market-cap/trading-at/%-YTD; keeps revenue/margins).
2. **ROOT depth / compression** (triple-confirmed): spawn/ask_analyst gained `as_section`
   recording the specialist's authored depth; submit_final REJECTS a report shorter than what
   the specialists authored (edit/refine OK, compression blocked). Charter directs commissioning.
3. **"memo" → "comprehensive report"** across charter + submit_final (the word nudged shortening);
   research subagent now COMPREHENSIVE (was "keep it tight"), budget 4k→8k.
4. **Engine edge bugs** (functional-QM, confirmed): excess_returns rejects ROE<=growth (negative
   P/B); rnpv rejects discount-rate-with-no-horizons (silent no-discount); safe_eval Pow cap
   64→1000 (was rejecting valid long-horizon discounting); get_institutional_summary derives
   quarters from today; consolidation gate tightened (last-few values @ 0.5%, was ±3% vs any).
5. **Conceptual fixes** (concept-QM): ANCHOR HONESTLY (kill the ~10-20% always-land-low tilt);
   FLOOR DISCIPLINE (cash for a burner is a melting runway, not a floor); PoS no-unjustified-
   upward-multiplier (the ARMP 1.5x); COMPLETENESS (management/ownership/insider + dated catalyst
   calendar + financing/dilution pro-forma — the CIO's deployment gaps).
   55 tests pass; lint clean.

### Undervalue-bias verdict (from the probabilities + concept-QM)
~80% correct stock-SELECTION (speculative names should trade above disciplined rNPV), ~20% a real
conservative FINAL-ANCHOR tilt (every report resolved below its own cross-checks) — now addressed
by ANCHOR HONESTLY. SIDU was wrongly below net cash; ARMP was if anything OVER-valued (unjustified
1.5x PoS). Not a category bias in the method.

### Test launched — 5 genuinely-cheap names (12:19Z, on the fully-fixed code)
NUS (Nu Skin, 0.33x book), JRVR (James River insurer, 0.28x book), ACR (ACRES REIT, 0.29x book),
MFIN (Medallion lender, 0.54x book), CPSS (auto lender, 0.65x book). If the engine values THESE
above price, there is no systematic underpricing bias. Results pending.

### Next
Monitor the 5 runs; analyze the undervalue result; status reports every ~30 min; end 14:06Z.

## Status report #2 — 12:58Z

**Two user requests handled this window:**

1. **Growing-revenue flukes replaced (D18).** The first complex-5 had tiny-base/lumpy "growth":
   KRRO $6.4M (lumpy collaboration milestones), RANI $1.6M (pre-commercial), STRO $102M but
   *declining* ($154M→$62M→$102M, lumpy partnership). Per the user ("be sure growing revenue is
   not a fluke from tiny revenue"), swapped for names with REAL, substantial revenue: **VSTM**
   ($0→$10M→$31M, RAF/MEK oncology), **VRCA** ($5M→$8M→$36M, derma drug-device), **CDXS**
   (Codexis, ~$70M, synthetic-biology/enzyme platform — the max cross-domain complexity test).
   Kept **STIM** ($71→$75→$149M, clean commercial) and **BZAI** ($38.6M real AI-chip ramp).

2. **Deterministic post-analysis price injection (D19).** `runner/report.py:_price_header`
   prepends, at PUBLISH time only, one header line: market price · engine FMV · implied
   upside/downside · floor. The price is read at the publish layer, NEVER by the price-blind
   engine/LLM (same seam as `portfolio/book.py`). 55 tests still green.

**In flight (10 runs, all on the price-injection code):**
- Cheap-value 5 — NUS, JRVR, ACR, MFIN, CPSS → settles the undervalue-bias question.
- Complex-growing 5 — STIM, VSTM, VRCA, BZAI, CDXS → cross-domain edge test.
- ~28 min in at report time; healthy (audit call counts climbing: STIM 27, CDXS 24, MFIN 20).
  Run IDs in `data/.cheap_runmap.txt` + `data/.complex_runmap.txt`.

**Next:** on completion confirm the price header renders + FMV-vs-price is sane; analyze both
batches; final report; delete `AUTONOMOUS_ACTIVE` at 14:06Z.
